Skip to content
BCI.INTEL
NLINKN1 Chip+PRIME.StudySYNCRStentrode+$200M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Companies/Boston Scientific Neuromodulation
activeFounded 1979

Boston Scientific Neuromodulation

HQ: Marlborough, MA, USACEO: Mike MahoneyHeadcount: 45,000+ (company-wide)www.bostonscientific.com
Funding Summary
Total Funding
Public (NYSE: BSX)
About

Boston Scientific is a major medical device company with a significant neuromodulation franchise spanning deep brain stimulation, spinal cord stimulation, and sacral neuromodulation. The Vercise Genus DBS system features multi-source current steering for precise therapeutic field shaping. Boston Scientific announced an agreement to acquire Nalu Medical for approximately $533M in October 2025, expanding its neurostimulation portfolio with Nalu's miniaturized peripheral nerve stimulation technology.

Products
bs-vercise-genus
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →